Key takeaways
- • Trial: SUSTAIN-6 (NCT01720446) — Phase 3, 3,297 participants over 104 weeks.
- • Drug studied: Ozempic (Semaglutide) — FDA-approved branded product.
- • Primary endpoint: Time to first major adverse cardiovascular event in adults with type 2 diabetes at high CV risk
- • Key result: 26% relative risk reduction in MACE on semaglutide vs placebo (HR 0.74, 95% CI 0.58-0.95)
- • Published: New England Journal of Medicine, 2016.
Study design
SUSTAIN-6 was a phase 3 randomized controlled trial enrolling 3,297 participants over 104 weeks. The trial studied Ozempic (Semaglutide) for cardiovascular outcomes and was published in New England Journal of Medicine in 2016.
Primary endpoint
Time to first major adverse cardiovascular event in adults with type 2 diabetes at high CV risk
Key results
| Measure | Value |
|---|---|
| Headline result | 26% relative risk reduction in MACE on semaglutide vs placebo (HR 0.74, 95% CI 0.58-0.95) |
| Participants | 3,297 |
| Duration | 104 weeks |
| Phase | Phase 3 |
Citation
SUSTAIN-6. Published in New England Journal of Medicine, 2016.
GLP1Zoom did not conduct this trial. We summarize published primary literature. For verbatim methods and full results, consult the primary publication and the ClinicalTrials.gov registry record.
Related
- Ozempic drug page — pricing, FDA status, side effects, alternatives
- All semaglutide trials
- GLP-1 clinical trials database
Other Ozempic trials
- SUSTAIN-1 — HbA1c reduction 1
Other Semaglutide trials
- STEP-1 (Wegovy) — Mean weight loss 14
- STEP-2 (Wegovy) — Mean weight loss 9
- STEP-3 (Wegovy) — Mean weight loss 16
- STEP-4 (Wegovy) — Participants continuing semaglutide lost an additional 7
- STEP-5 (Wegovy) — Mean weight loss 15
Important: This trial was conducted on the FDA-approved branded product Ozempic. Compounded versions of Semaglutide have NOT been studied in equivalent randomized controlled trials, and their efficacy and safety profile may differ.
GLP1Zoom is an affiliate-only comparator. We cite published trials; we do not conduct them. This page is informational and is not a substitute for personalized medical advice — always confirm any treatment decision with your prescribing clinician. Full disclaimer.